Table 1.
Association between the EGFR gene mutation and clinicopathological features of lung adenocarcinoma
| Clinicopathological features | Total lung adenocarcinoma (n=424) | Biopsy specimen (n=298) | Surgical specimen (n=126) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| EGFR mutation (+) | EGFR mutation (‒) | P | EGFR mutation (+) | EGFR mutation (‒) | P | EGFR mutation (+) | EGFR mutation (‒) | P | |
| Age (years) | |||||||||
| ≤60 | 132 (54.5%) | 110 (45.5%) | 0.759 | 92 (53.2%) | 81 (46.8%) | 0.835 | 40 (58.0%) | 29 (42.0%) | 0.849 |
| >60 | 102 (56.0%) | 80 (44.0%) | 68 (54.4%) | 57 (45.6%) | 34 (59.6%) | 23 (40.4%) | |||
| Gender | |||||||||
| Female | 153 (73.9%) | 54 (26.1%) | 0.000* | 103 (73.0%) | 38 (27.0%) | 0.000* | 50 (75.8%) | 16 (24.2%) | 0.000* |
| Male | 81 (37.3%) | 136 (62.7%) | 57 (36.3%) | 100 (63.7%) | 24 (40.0%) | 36 (60.0%) | |||
| Smoking status | |||||||||
| Smoker | 52 (34.2%) | 100 (65.8%) | 0.000* | 38 (34.5%) | 72 (65.5%) | 0.000* | 14 (33.3%) | 28 (66.7%) | 0.000* |
| Nonsmoker | 182 (66.9%) | 90 (33.1%) | 122 (64.9%) | 66 (35.1%) | 60 (71.4%) | 24 (28.6%) | |||
| Pathological degree | |||||||||
| Well/moderated | 192 (59.8%) | 129 (40.2%) | 0.001* | 121 (57.6%) | 89 (42.4%) | 0.036* | 71 (64.0%) | 40 (36.0%) | 0.001* |
| Poor | 42 (40.8%) | 61 (59.2%) | 39 (44.3%) | 49 (55.7%) | 3 (20.0%) | 12 (80.0%) | |||
| Clinical stages | |||||||||
| Stage I+II+III | 98 (54.1%) | 83 (45.9%) | 0.709 | 28 (44.4%) | 35 (55.6%) | 0.097 | 70 (59.3%) | 48 (40.7%) | 0.883 |
| Stage IV | 136 (56.0%) | 107 (44.0%） | 132 (56.2%) | 103 (43.8%) | 4 (50.0%) | 4 (50.0%) | |||
| Maximum diameter of tumor | |||||||||
| ≤3cm | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | 51(63.0%) | 30(37.0%) | 0.278 |
| >3, ≤5 cm | ‒ | ‒ | ‒ | ‒ | 18(54.5%) | 15(45.5%) | |||
| >5, ≤7cm | ‒ | ‒ | ‒ | ‒ | 4(57.1%) | 3(42.9%) | |||
| >7cm | ‒ | ‒ | ‒ | ‒ | 1(20.0%) | 4(80.0%) | |||
| Lymph node metastasis | |||||||||
| Positive | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | 28 (59.6%) | 19 (40.4%) | 0.882 |
| Negative | ‒ | ‒ | ‒ | ‒ | 46 (58.2%) | 33 (41.8%) | |||
| Pleural metastasis | |||||||||
| Positive | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | 35 (56.5%) | 27 (43.5%) | 0.609 |
| Negative | ‒ | ‒ | ‒ | ‒ | 39 (60.9%) | 25 (39.1%) | |||
Notes: For the Chi-square test，*P<0.05 is considered statistically significant, “-” missing information.